RESUMO
Objectives: To compare the anti platelet effects of locally manufactured clopidogrel with the anti platelet effect of clopidogrel manufactured by multinational pharmaceutical abroad. Methodology: A total of 118 subjects were enrolled, 18 to 65 years of age, who presented with suspected ischemic heart disease and were randomly assigned to receive either drug A (Pidogrel) or drug B (Plavix) in a double blind manner for 7 days. Platelet aggregation was measured in both the groups at baseline and at final visit. Results: Base line platelet aggregability in both drug groups was not significantly different (p=0.317) Mean reduction in platelet aggregation by drug-A was 8.47+/- 0.45 ohms (p<0.001) and mean reduction in platelet aggregation by drug-B was 8.62+/- 0.46 (p<0.001). The difference in platelet aggregability at day 7(follow up) between the two groups was not statistically significant i.e., was the same. Conclusion: Locally manufactured clopidogrel is equally effective as that manufactured by the multinational company abroad giving us the added advantage of cost effectiveness.
RESUMO
Adrenocarcinoma is a rare disease with a poor prognosis. As a practical classification, adrenal carcinomas divide to two categories: functional and nonfunctional. Adjurent radiotherapy and chemotherapy is useful for palliation. The aim of this report is to introduce one case of large nonfunctional adrenocarcinoma. A 46 years old-male with ambiguous abdomen pain and orchidoepididymitis reffered to clinic in 2006. Physical examination revealed grade III fixed varicocele with left orchidoepididymitis. Sonography and computed tomography scan showed a massive lesion on left adrenal. Adrenal function test was normal, therefore nonfunctional adrenocarcinoma is diagnosed. This patient underwent open adrenalectomy. Then the patient introduced to chemoradiotherapy in oncology center. After six months, the patient suffered from multiple liver metastases and one year later was expired